The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical efficacy of NXP900, a YES1/SRC kinase inhibitor in esophageal squamous cancer models.
 
Sweta Dash
No Relationships to Disclose
 
Katherine Nyswaner
No Relationships to Disclose
 
Mungo J.B. Harvey
Research Funding - Nuvectis Pharma (Inst)
 
Ben King
Research Funding - Nuvectis Pharma (Inst)
 
Allison Woods
Employment - Nuvectis Pharma
Stock and Other Ownership Interests - Nuvectis Pharma
 
Neil O. Carragher
Research Funding - Nuvectis Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Nuvectis Pharma
 
Asier Unciti
Research Funding - Nuvectis Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Nuvectis Pharma
 
Enrique Poradosu
Employment - Nuvectis Pharma
Leadership - Nuvectis Pharma
Stock and Other Ownership Interests - Nuvectis Pharma
 
John Brognard
No Relationships to Disclose